Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.92 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.92 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651627 | 1.00 | PIK3CD (1.00) | PIK3CDCSNK1EPIK3R1PIK3CG | |
| SCHEMBL15557443 | 1.00 | PIK3CD (1.00) | PIK3CDCSNK1EPIK3R1PIK3CG | |
| SCHEMBL15555369 | 1.00 | PIK3CD (1.00) | PIK3CDCSNK1EPIK3R1PIK3CG | |
| SCHEMBL29456306 | 1.00 | PIK3CD (1.00) | PIK3CDCSNK1EPIK3R1PIK3CG | |
| SCHEMBL29651741 | 1.00 | PIK3CD (1.00) | PIK3CDCSNK1EPIK3R1PIK3CG | |
| Umbralisib SCHEMBL15557158 | 0.96 | PIK3CD (1.00) | PIK3CDCSNK1EPIK3R1PIK3CG | |
| Umbralisib SCHEMBL15556335 | 0.96 | PIK3CD (1.00) | PIK3CDCSNK1EPIK3R1PIK3CG | |
| Umbralisib SCHEMBL15557416 | 0.96 | PIK3CD (1.00) | PIK3CDCSNK1EPIK3R1PIK3CG | |
| Umbralisib SCHEMBL29358460 | 0.96 | PIK3CD (1.00) | PIK3CDCSNK1EPIK3R1PIK3CG | |
| Umbralisib SCHEMBL30341857 | 0.96 | PIK3CD (1.00) | PIK3CDCSNK1EPIK3R1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | claimed |
| EP-4292596-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | Curon Biopharmaceutical (Shanghai) Co., Limited (CN) | 2023-12-20 | — | — | EP | claimed |
| CN-117222413-A | Methods and combinations for treating tumors | 同润生物医药(上海)有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-111635406-A | Improved forms of a selective inhibitor of PI3K for use in pharmaceutical formulations | 理森制药股份公司 | 2020-09-08 | — | — | CN | claimed |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | claimed |
| EP-2870157-B1 | SELECTIVE PI3K DELTA INHIBITORS | RHIZEN PHARMACEUTICALS S A (CH) | 2017-08-30 | — | — | EP | claimed |
| EP-2496567-B1 | NOVEL BENZOPYRAN KINASE MODULATORS | RHIZEN PHARMACEUTICALS S A (CH) | 2017-07-12 | — | — | EP | claimed |
| EP-3149000-A1 | IMPROVED FORMS OF A PI3K DELTA SELECTIVE INHIBITOR FOR USE IN PHARMACEUTICAL FORMULATIONS | Rhizen Pharmaceuticals S.A. (CH) | 2017-04-05 | — | — | EP | claimed |
| US-9475818-B2 | Selective PI3K delta inhibitors | RHIZEN PHARMACEUTICALS SA (CH) | 2016-10-25 | — | — | US | claimed |
| US-20150361083-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-12-17 | — | — | US | claimed |
| WO-2015181728-A1 | IMPROVED FORMS OF A PI3K DELTA SELECTIVE INHIBITOR FOR USE IN PHARMACEUTICAL FORMULATIONS | RHIZEN PHARMACEUTICALS SA (CH) | 2015-12-03 | — | — | WO | claimed |
| EP-2870157-A1 | SELECTIVE PI3K DELTA INHIBITORS | Rhizen Pharmaceuticals S.A. (CH) | 2015-05-13 | — | — | EP | claimed |
| US-20140011819-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2014-01-09 | — | — | US | claimed |
| WO-2014006572-A1 | SELECTIVE PI3K DELTA INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-01-09 | — | — | WO | claimed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | claimed |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PIK3CD 70/4885CSNK1E 109/4885PIK3R1 95/4885 |
| US-20140011819-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | PIK3CD, PIK3R5, PIK3C2B | PIK3CD 1/4885CSNK1E 78/4885PIK3R1 9/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PIK3CD 70/4885CSNK1E 109/4885PIK3R1 95/4885 |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PIK3CD 70/4885CSNK1E 109/4885PIK3R1 95/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | PIK3CD 103/4885CSNK1E 98/4885PIK3R1 53/4885 |
| US-20150361083-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | PIK3CD, PIK3R5, PIK3C2B | PIK3CD 1/4885CSNK1E 78/4885PIK3R1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.